Schedule 13G ownership disclosure

Beta Bionics Inc

Common Stock · CUSIP: 08659B102

Event date: 2026-09-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Soleus Private Equity Fund II, L.P.

    Shares: 1,003,961.00 · Class: 1.8%

  • Soleus Private Equity GP II, LLC

    Shares: 1,003,961.00 · Class: 1.8%

  • Soleus PE GP II, LLC

    Shares: 1,003,961.00 · Class: 1.8%

  • Soleus Capital Master Fund, L.P.

    Shares: 3,783,237.00 · Class: 6.8%

  • Soleus Capital, LLC

    Shares: 3,783,237.00 · Class: 6.8%

  • Soleus Capital Group, LLC

    Shares: 3,783,237.00 · Class: 6.8%

  • Soleus Capital Management, L.P.

    Shares: 4,787,198.00 · Class: 8.6%

  • Soleus GP, LLC

    Shares: 4,787,198.00 · Class: 8.6%

  • Levy Guy

    Shares: 4,828,619.00 · Class: 8.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001213900-26-117545
Form type
SCHEDULE 13G/A
Filer
Soleus Capital Master Fund, L.P.
CIK
CIK 1812275
Filed
Nov 09, 2026
Reporting period
Sep 30, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub